Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugspriority health formulary coverage & PA update | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentpriority healthPolicy N/A

    Priority Health Medicare Employer Group Formulary (Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the covered prescription drugs, formulary structure, restrictions (prior authorization, quantity limits, step therapy), and exception/transition processes for Priority Health Medicare Employer Group members.

    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare Employer Group Formulary (Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJune 1, 2026
    Last ReviewMay 21, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug entry lists 'PA' before dispensing to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6/1/26formulary current as of
    v15document version
    30 daystransition supply
    72 hrsstandard exception time
    24 hrsexpedited exception
    30-dayTier 5 supply limit

    Coverage Criteria and Formulary Rules

    General formulary coverage

    Covered when ALL of the following general conditions are met:

    General coverage conditions: Drug is listed on the Priority Health Medicare formulary, is medically necessary, is dispensed at a Priority Health Medicare network pharmacy, and other plan rules (e.g., PA, QL, ST, B/D, HI, LA) are followed.

    See formulary listings and Requirements/Limits for product-specific controls.

    Transition and emergency supply

    Temporary coverage provisions:

    Transition supply: Members taking non-formulary or restricted drugs will be provided a temporary 30-day supply (31 days for long-term care residents) while pursuing a formulary exception or transition, unless the prescription is written for fewer days.30 days

    Standard temporary transition supply; see long-term care exception (31 days).

    Policy Summary
    Payerpriority health
    PolicyPriority Health Medicare Employer Group Formulary (Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJune 1, 2026
    Last ReviewMay 21, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug entry lists 'PA' before dispensing to avoid claim denial.
    SourceLink
    On This Page
    Coverage Criteria and Formulary RulesAbbreviations, Codes and Quantity ExamplesPrior Authorization, Step Therapy, Documentation, and Denial RisksBackground InformationLegend and AbbreviationsContinuation and Transition ProtectionsStep Therapy Rules and NotesQuantity Limits by Product (Examples)Site-of-Care and Benefit Routing
    New member transition: For each drug not on formulary or with a restriction, Priority Health Medicare may cover a temporary 30-day supply during the first 90 days of membership while a coverage decision or exception is pursued.30 days

    Coverage ends after temporary supply if exception not approved.

    Level-of-care change: Members experiencing a level-of-care change will be provided a transition supply of at least 30 days of medication unless the prescription is written for fewer days.30 days

    Applies when site-of-care or care-level changes occur.

    General coverage rule for listed formulary products

    Covered when product is on formulary subject to noted prior authorization and quantity limits:

    Formulary coverage rule: Drug is covered according to its assigned formulary tier (T1–T6). Where Prior Authorization (PA) is indicated in the Requirements/Limits column, PA must be obtained prior to coverage. Where a Quantity Limit (QL) is specified, covered supply is limited to the stated amount per time period.see QL per product

    B/D indicates Part B vs Part D billing; Tier 5 specialty drugs limited to 30-day supply.

    Formulary tier and restriction rules

    Coverage is determined by formulary tier with specific quantity limits and prior authorization requirements applied where noted.

    Tier-based coverage: Drugs are assigned to formulary tiers (T1–T6); coverage, cost-sharing, and supply rules follow the tier assignment. Tier 5 (Specialty) drugs are limited to a 30-day supply unless otherwise specified.

    Refer to tier legend for definitions.

    Prior authorization and quantity limits: If a product's Requirements/Limits field lists PA, prior authorization is required before coverage. If QL is listed, the allowed amount is restricted to the stated QL (e.g., TRULICITY PA; QL 2 mL per 28 days; ENTRESTO QL 240 EA per 30 days).see product QL

    Providers must submit documentation to support PA and requested QL.

    Formulary coverage with tier and requirement flags

    Coverage and access are governed by tier assignment plus any listed requirement/limit flags. Examples below reflect how the document structures coverage rules for select product groups.

    Vaccine and select injectables: Coverage of vaccines and select injectable products is subject to tier assignment and any explicit quantity limits (QL) or Part B/Part D designation (B/D). Specific vaccines list QL values where applicable (e.g., ACTHIB QL 1 EA per 365 days; MRESVIA QL 0.5 mL per 720 days; SHINGRIX QL 1 mL per 999 days).see code groups

    Providers must follow PA/QL/B-D billing instructions where flagged.

    Specialty injectables and bone agents: Certain specialty injectables and metabolic bone disease agents are assigned PA and QL requirements (e.g., EVENITY PA; QL 2.34 mL per 30 days; TERIPARATIDE PA; QL per product).see product QLs

    PA must be obtained per formulary before coverage is approved.

    Prior authorization required

    Specialty and high-cost products:

    PA-required specialty agents: Certain specialty agents require prior authorization (PA) and often have quantity limits; examples include EVENITY, TERIPARATIDE, TYMLOS, YORVIPATH, CYSTADROPS, CYSTARAN, and OXERVATE.see code groups

    PA must be obtained per formulary before coverage is approved.

    PA and QL enforcement: Failure to obtain required prior authorization or exceeding listed quantity limits may result in claim denial or non-coverage for specialty/high-cost drugs.

    Providers should submit required documentation per PA process.

    Step therapy requirements

    Step therapy and utilization management for ophthalmics:

    Ophthalmic step therapy: Selected ophthalmic anti-inflammatories and prostaglandin/prostamide products are subject to Step Therapy (ST) where indicated (entries flagged 'ST' such as travoprost, difluprednate, loteprednol).N/A

    Follow ST protocol and document prior therapeutic trials when requesting authorization.

    Coverage with utilization controls

    Formulary coverage and utilization controls — drugs are categorized by tier and may have QL, PA, LA, B/D or other restrictions:

    Formulary assignment: Drugs are assigned formulary tiers (T1–T6); tier determines cost-sharing and supply rules (e.g., Tier 5 = 30-day supply).

    See tier legend for definitions and supply rules.

    Utilization controls: If a drug row lists PA, LA, QL, ST, or B/D it is subject to that requirement (e.g., INCRUSE ELLIPTA QL 30 EA per 30 days; SPIRIVA RESPIMAT QL 4 GM per 30 days; TRIKAFTA PA; QL 84 EA per 28 days).

    Claims must meet listed PA and QL rules to be covered; LA and B/D affect availability and benefit routing.

    Drugs labeled ED (Excluded Drug) in this formulary are not normally covered under a Medicare Prescription Drug Plan. The formulary defines ED as a category where the prescription is not ordinarily payable by the Part D benefit, and amounts paid by the enrollee for ED drugs do not count toward total drug costs (they do not help the member reach catastrophic coverage) and recipients of extra help will not receive assistance for ED drugs.

    The formulary legend defines ED = Excluded Drug and explains the implications for billing and benefit calculations. Specifically, ED drugs are not normally covered by the Medicare Part D benefit and payments for ED drugs are excluded from measures such as progress toward catastrophic coverage. Providers and billing staff should treat ED-marked items as outside the plan's Part D coverage unless alternative coverage (e.g., Part B or a medical benefit) is documented and allowable.

    Within the extract provided there are no broad clinical exclusions that remove whole therapeutic classes from coverage; instead the document uses utilization controls (for example, PA, QL, ST, B/D, HI, LA) and the ED flag for specific products. This means most coverage decisions in the excerpt are implemented through prior authorization, quantity limits, step therapy, or benefit routing rather than blanket clinical exclusions.

    The extract's formulary legend includes the ED abbreviation but does not list a comprehensive excluded-drug section in these chunks; rather, ED appears as a requirements/limits flag on individual rows. Reviewers should consult the product rows and the legend together to identify which specific entries are flagged ED.

    Examples of products in the extract that are flagged ED include several topical and dermatologic preparations. The listing shows entries such as RENOVA and RENOVA PUMP marked ED, salicylic acid external lotion marked ED, and multiple urea external products (cream/gel) listed with Requirements/Limits = ED.

    The formulary explicitly notes that rows with Requirements/Limits = ED are not covered under the Part D formulary. For example, RENOVA and certain urea topical products show ED in their requirements/limits designation, indicating exclusion from coverage.

    Additional specific products marked ED in the extract include selected genitourinary and reproductive therapy items. The listing shows phenazopyridine HCl (100 mg, 200 mg) and several fertility-related agents (e.g., cetrorelix / CETROTIDE) with Requirements/Limits = ED, indicating these items are excluded from Part D coverage in the displayed segment.

    The document identifies infertility and reproductive therapy products among those annotated ED. For example, CETROTIDE SUBCUTANEOUS KIT 0.25 MG and related entries are shown with Requirements/Limits = ED, denoting exclusion in this formulary extract.

    Some index rows display the ED flag in respiratory and other sections. For example, the respiratory segment shows benzonatate with an ED designation on the index row in this extract, demonstrating that ED annotations can appear at the row/index level for a range of agents.

    Abbreviations, Codes and Quantity Examples

    Abbreviationsmixed
    B/DPart B vs. Part D - drug may require prior authorization and may be covered differently under Medicare Part B (medical) or Part D (prescription) depending on circumstances.
    EAEach
    EDExcluded Drug - not normally covered in a Medicare Prescription Drug Plan; cost does not count toward total drug costs for catastrophic coverage; extra help not available for this drug.
    HIHome Infusion
    LALimited Availability
    NENo Express Scripts
    PAPrior Authorization
    QLQuantity Limits
    STStep Therapy
    MLMilliliters
    1–10 of 11
    1/2
    Common Abbreviations (continued)mixed
    T1Preferred generic
    T2Generic
    T3Preferred brand
    T4Non-preferred drug
    T5Specialty
    T6Infertility
    Selected Formulary Products with Quantity Limits (Examples)NDC
    ARIKAYCEQL example: 235.2 ML per 28 days (illustrative)
    LIDOCAINE_PATCHESQL example: 90 EA per 30 days
    FENTANYL_PATCHQL example: 10 EA per 30 days
    XIFAXAN_200MGPA; QL 9 EA per 30 days
    XIFAXAN_550MGPA; QL 60 EA per 30 days
    VANCOMYCIN_ORAL_CAPSULE_125MGQL 80 EA per 30 days (125 mg)
    VANCOMYCIN_ORAL_CAPSULE_250MGQL 160 EA per 30 days (250 mg)
    Formulary Entries with PA/QLNDCCovered
    XIFAXAN_200MGPA; QL (9 EA per 30 days)
    XIFAXAN_550MGPA; QL (60 EA per 30 days)
    Vancomycin FormulationsNDCCovered
    VANCOMYCIN_IV_RECONSTITUTED_1GMHome Infusion (HI) for IV reconstituted 1 gm; tier varies
    VANCOMYCIN_ORAL_CAPSULE_125MGOral capsule 125 mg; QL 80 EA per 30 days
    VANCOMYCIN_ORAL_CAPSULE_250MGOral capsule 250 mg; QL 160 EA per 30 days
    Anticonvulsants / Specialty AgentsNDCCovered
    BRIVARACETAMPA; QL examples (oral solution/tablet)
    EPIDIOLEXPA; QL (500 ML per 30 days)
    FINTEPLAPA; QL (360 ML per 30 days)
    XCOPRIPA; QL (varies by strength)
    Placeholder - No CPT/HCPCS/ICD codes in excerptmixed
    No codes listed
    Drugs with Specified Strengths (examples)NDC
    TRULICITY_AUTOINJECTORPA; QL (2 ML per 28 days)
    XARELTO_10MGQL (30 EA per 30 days)
    XARELTO_15MGQL (60 EA per 30 days)
    ENOXAPARIN_PREFILLED_30MGQL (18 ML per 30 days)
    ENOXAPARIN_PREFILLED_40MGQL (24 ML per 30 days)
    ENOXAPARIN_PREFILLED_60MGQL (36 ML per 30 days)
    INVEGA_SUSTENNA_PREFILLEDQL examples by strength (ml per 30 days)
    Formulary drug listings and limits (cardiovascular examples)NDC
    CANDESARTAN_4MGTier 2; QL 240 EA per 30 days
    CANDESARTAN_8MGTier 2; QL 120 EA per 30 days
    CANDESARTAN_16MGTier 2; QL 60 EA per 30 days
    CANDESARTAN_32MGTier 2; QL 30 EA per 30 days
    IRBESARTAN_75MGTier 1; QL 120 EA per 30 days
    IRBESARTAN_150MGTier 1; QL 60 EA per 30 days
    IRBESARTAN_300MGTier 1; QL 30 EA per 30 days
    LOSARTAN_25MGTier 1; QL 90 EA per 30 days
    LOSARTAN_50MGTier 1; QL 60 EA per 30 days
    LOSARTAN_100MGTier 1; QL 60 EA per 30 days
    1–10 of 20
    1/2
    Formulary requirement codes and examplesmixed
    PAPrior Authorization required for certain products (see entry)
    QLQuantity limits specified per product and strength (see entry)
    HIHome Infusion requirement noted for some IV products
    B/DMedicare Part B vs Part D note applies for specified items
    STStep therapy requirement applies to certain ophthalmic and dermatologic agents
    Sample formulary drug entries (partial)NDC
    LISINOPRIL_2.5MGTier 1; example strengths listed
    LISINOPRIL_10MGTier 1; QL 120 EA per 30 days
    LISINOPRIL_20MGTier 1; QL 60 EA per 30 days
    BENAZEPRIL_5MGTier 1; QL 480 EA per 30 days
    BENAZEPRIL_10MGTier 1; QL 240 EA per 30 days
    BENAZEPRIL_20MGTier 1; QL 120 EA per 30 days
    BENAZEPRIL_40MGTier 1; QL 60 EA per 30 days
    ENALAPRIL_2.5MGTier 1; QL 480 EA per 30 days
    ENALAPRIL_5MGTier 1; QL 240 EA per 30 days
    Biologic / Biosimilar entriesNDC
    REPATHAPA; QL (2 ML per 28 days)
    DUPIXENT_300MG_2MLPA; QL (8 ML per 30 days)
    Selected Vaccines and Quantity-Limited ProductsNDCCovered
    SHINGRIXQL (1-2 EA per long interval; see formulary)
    AREXVYQL (1 EA per 720 days)
    MRESVIAQL (0.5 ML per 720 days)
    PENBRAYAQL (2 EA per 720 days)
    JYNNEOSRequirements/Limits = B/D
    IMOVAX_RABIESRequirements/Limits = B/D
    Metabolic Bone Disease / Specialty InjectablesNDCCovered
    EVENITYPA; QL (2.34 ML per 30 days)
    TERIPARATIDE_PENPA; QL (2.48 ML per 30 days)
    TYMLOSPA; QL (1.56 ML per 30 days)
    ZOLEDRONIC_ACID_IVB/D for IV formulations
    Ophthalmic agents with PA/QL/STNDCCovered
    RESTASIS_MULTIDOSE_0.05%QL (5.5 ML per 30 days)
    CYSTADROPSPA; QL (20 ML per 30 days)
    OXERVATEPA; QL (28 ML per 30 days)
    LUMIGAN_0.01%tiered
    DIFFLUPREDNATEST (step therapy) applies
    Otic and Respiratory agentsNDCCovered
    CIPROFLOXACIN_DEXAMETHASONE_OTICQL (7.5 ML per 30 days)
    ALBUTEROL_HFAQL (17-36 GM per 30 days depending on NDC)
    INCRUSE_ELLIPTAQL (30 EA per 30 days)
    Placeholder - No billing codes listedmixed
    No codes listed

    Prior Authorization, Step Therapy, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Priority Health requires prior authorization (PA) for many drugs listed in the formulary. Prescribers must request and receive approval before the drug is dispensed; failure to obtain required PA may result in noncoverage or claim denial.

    • PA applies to many specialty, high‑cost, and selected non-specialty products across the formulary (see PA flags in drug listings).
    • Common PA triggers: specialty tier drugs (T5), selected oncology, immunologic, pulmonary, genetic/enzyme replacement, and other high-cost agents.
    • Examples of drugs requiring PA include (non‑exhaustive): XIFAXAN (200 mg and 550 mg), selected anticonvulsants (brivaracetam, EPIDIOLEX, rufinamide, etc.), DIFICID formulations, many oncology agents (e.g., VENCLEXTA, TAGRISSO), specialty biologics (e.g., DUPIXENT, REPATHA), pulmonary/cystic fibrosis products (TRIKAFTA, ORKAMBI), and multiple other PA‑flagged items throughout the formulary.
    Documentation Required

    Part B vs Part D — Documentation May Be Required

    Some drugs are subject to a Part B vs. Part D (B/D) determination and may require additional documentation from the prescribing provider to establish the setting of use and benefit routing.

    • When a B/D flag appears, submit clinical documentation describing the drug’s use and administration setting to support Part B coverage when applicable.
    • Examples where B/D is indicated: certain infused or injectable agents and some inhalation/medical‑benefit products (see drug line entries).
    Documentation Required

    Quantity Limits and Documentation

    Quantity limits (QL) and limited‑availability (LA) flags listed in the formulary are enforced on claims and prior authorizations. Providers must adhere to the stated QLs or request exceptions with supporting clinical justification.

    • Submit requested quantity and intended days’ supply on PA submissions. QLs shown in each drug row (e.g., XIFAXAN 200 mg QL = 9 EA per 30 days; XIFAXAN 550 mg QL = 60 EA per 30 days).
    • Tier 5 drugs are limited to 30‑day supply only unless otherwise noted.
    • LA (Limited Availability) items may be available only at select pharmacies — check Provider/Pharmacy Directory or contact Customer Care.
    Step Therapy

    Step Therapy (ST) Requirements

    Step therapy (ST) requirements are used for select agents: prescribers must document prior trials of required drugs or clinical rationale for bypassing the step protocol when requesting an exception.

    • DIFICID oral suspension and tablets carry ST plus QL (see entries) — prescribers must document prior use/ failure of preferred therapy where applicable.
    • ST is referenced across multiple classes (e.g., some antidepressants, ophthalmic agents, paliperidone ER strengths) — follow the ST flag in the formulary and provide prior trial records in PA/exception requests.
    • If requesting an exception to ST, include the prescriber’s supporting statement explaining why the step requirement is medically inappropriate or harmful; exception decisions are generally rendered within 72 hours (24 hours for expedited requests).
    Documentation Required

    Prior Authorization Documentation and Timing

    Prescribers must include supporting clinical documentation with PA requests: indication, prior therapy trials and dates, clinical rationale for the requested agent, relevant labs or imaging when applicable, and any B/D information needed to route the claim correctly.

    • Priority Health generally must make a determination within 72 hours of receiving the prescriber’s supporting statement; expedited reviews (24 hours) are available when waiting could seriously harm the member.
    • Documentation supports PA, QL exceptions, ST exemptions, and B/D determinations — incomplete submissions may delay or trigger denials.
    Denial Risk

    Denial Risk from Unmet Utilization Controls

    Utilization controls — PA, QL, ST, LA, NE, B/D, and ED — can lead to claim denials when requirements are not met. Verify flags on the formulary and secure necessary authorizations before dispensing.

    • ED (Excluded Drug) entries are not covered and will be denied — examples include certain topical/emollient formulations and listed vitamins or pumps marked ED.
    • Drugs marked PA or with QL exceedances may be denied at claim adjudication without an approved authorization.
    • LA or NE flags may limit where a product can be obtained; failing to use an approved source can cause claim processing issues.

    Background Information

    Background: biological products are complex therapies distinct from small-molecule generics; some biologics have biosimilars or interchangeable biosimilars that may be substituted per applicable law. The formulary treats biologic and biosimilar entries individually, and many biologic agents in the extract are listed with PA and specific quantity limits that must be followed for coverage decisions.

    Legend and Abbreviations

    inv-112: Generic drug — definition
    Generic drug — definitionA generic drug is FDA‑approved to have the same active ingredient as the brand‑name drug and may be substituted per state law
    Original biological product / biosimilarBiological products have biosimilars; interchangeable biosimilars may be substituted per state law
    PA (Prior Authorization)Requires approval from Priority Health Medicare before filling; lack of approval may result in non‑coverage
    inv-113: Original biological product / biosimilar — definition
    Original biological product / biosimilarBiosimilars are analogous alternatives to original biological products; interchangeable biosimilars may be substituted without a new prescription depending on state law
    Biosimilar substitution noteBiological products are more complex and use biosimilars rather than generic equivalents
    Reference to Evidence of CoverageSee Evidence of Coverage, Chapter 5, Section 3.1 for Part D coverage details
    inv-114: PA — Prior Authorization definition
    PA — Prior AuthorizationPriority Health Medicare requires prior authorization for certain drugs; approval must be obtained before dispensing or coverage may be denied
    PA documentationPhysician may need to submit information describing drug use and setting (Part B vs Part D determinations) and clinical rationale
    Consequence of no PAFailure to obtain PA may result in non‑coverage or denial
    inv-114-duplicate: PA / QL / ST — key definitions (supporting citations)
    PA — Prior Authorization (definition)Requires approval from the plan before prescription is filled; lack of approval may result in non‑coverage
    Quantity Limits (QL) — definitionMaximum quantity allowed per time period (EA, ML, GM) as specified for each product
    Step Therapy (ST) — definitionRequirement to try specified drugs first before covering alternatives
    inv-116: Tiers — tier definitions
    T1 — Preferred genericLowest tier (preferred generic)
    T3 — Preferred brandPreferred brand tier
    T5 — SpecialtySpecialty tier; Tier 5 drugs are limited to 30‑day supply
    T6 — InfertilityInfertility tier
    inv-117: HI — Home Infusion definition
    HI — Home InfusionIndicates the drug may be administered via home infusion and may be covered under the medical benefit; contact Customer Care for details
    B/D — Part B vs Part DFlag indicating drug may be billed under Medicare Part B or Part D depending on setting/use
    NE — No Express ScriptsNot available via Express Scripts Home Delivery
    inv-118: Abbreviations — legend meanings (T1-T6, PA, QL, ST, NE, B/D)
    Formulary abbreviations (key)B/D = Part B vs Part D; EA = Each; ED = Excluded Drug; HI = Home Infusion; LA = Limited Availability; NE = No Express Scripts; PA = Prior Authorization; QL = Quantity Limits; ST = Step Therapy; ML = Milliliters; GM = Grams
    EA — EachUnit used for count‑based QLs (EA)
    ML / GM unitsVolume (mL) and weight (g) units used for QLs where applicable
    inv-119: PA — Prior Authorization note (definition duplicate/legend)
    PA — Prior Authorization (plan action)Plan requires prescriber to get approval before drug is filled; lack of approval may result in noncoverage
    ST — Step TherapyMember may be required to try specified preferred drugs before coverage of non‑preferred alternatives
    QL — Quantity LimitsMaximum allowed quantity per period must be adhered to when submitting claims and authorizations
    inv-120: QL — Quantity Limits definition
    QL — Quantity Limits (definition)Maximum quantity allowed per specified time period (examples shown in the formulary: '30 EA per 30 days', '2 ML per 28 days', etc.)
    ST — Step Therapy (definition)Requirement to try specified drugs first before coverage of alternatives
    ED — Excluded Drug (definition)Drug not normally covered in a Medicare Prescription Drug Plan
    inv-121: LA — Limited Availability definition
    LA — Limited AvailabilityIndicates product supply or access limitations noted by the plan
    NE — No Express ScriptsNot available through Express Scripts home delivery
    B/D — Part B vs Part DFlag used when billing may be Part B or Part D depending on setting/use
    inv-122: T5 — Specialty tier note (30-day supply rule)
    T5 — Specialty tier noteTier 5 drugs are specialty; note indicates Tier 5 drugs are 30‑day supply only
    T1–T4 summaryT1 = Preferred generic; T2 = Generic; T3 = Preferred brand; T4 = Non‑preferred drug
    T6 — InfertilityT6 reserved for infertility agents
    inv-123: Abbreviations (formulary key) — expanded legend
    Formulary legend (expanded)Lists T1–T6, B/D, EA, ED, HI, LA, NE, PA, QL, ST, ML, GM — used across the formulary entries
    EA — Each (unit)Used for countable dose limits (EA)
    ST — Step Therapy (legend)Indicates step therapy requirement may apply where flagged
    inv-124: Tier definitions / abbreviations — T1-T6 and others
    Tiers (T1–T6)T1 Preferred generic; T2 Generic; T3 Preferred brand; T4 Non‑preferred; T5 Specialty; T6 Infertility
    PAPrior Authorization — plan approval required before coverage
    QLQuantity Limit — maximum allowed per specified time period
    inv-125: Legend abbreviations — formulary legend definitions
    PA (Prior Authorization)Requires prescriber to obtain plan approval prior to dispensing; failure to obtain PA may lead to denial
    QL (Quantity Limits)Specified maximum quantities (EA/ML/GM) per defined period must be followed
    ED (Excluded Drug)Not normally covered under Medicare Part D; payments do not count toward total drug costs
    inv-126: QL — Quantity Limits as specified
    QL — as specifiedQuantity Limits are expressed per period (e.g., EA per 30 days; ML per 28/30 days)
    Examples unitsEA = Each; ML = Milliliters; GM = Grams — used in QL expressions
    Apply QL to claims/PAQL values should be used to support authorizations and claims submissions
    inv-127: PA — Prior Authorization required before coverage
    PA — Prior Authorization requirementPrior Authorization required before coverage for drugs flagged 'PA' in the formulary
    PA documentation timeframeExceptions and PA decisions referenced elsewhere indicate standard decision times (see policy) — prescriber support required
    Denial riskCoverage may be denied if PA is not obtained
    inv-128: T1-T6 — tiers summary
    T1–T6 summaryFormulary tiers where T1 = Preferred generic, T5 = Specialty, T6 = Infertility
    Tier implicationsTier determines cost‑sharing and supply rules (e.g., Tier 5 = 30‑day supply)
    Reference noteSee formulary legend for full abbreviations and rules
    inv-129: Tier definitions and abbreviations — repeated legend
    Tier definitions (concise)T1 Preferred generic; T2 Generic; T3 Preferred brand; T4 Non‑preferred; T5 Specialty; T6 Infertility
    Common abbreviationsPA, QL, ST, ED, HI, LA, B/D — used throughout formulary entries
    Tier 5 supply ruleTier 5 items limited to 30‑day supply as noted in legend

    Continuation and Transition Protections

    Continuation/Transition protections

    Protections for members already taking drugs and during care-level changes:

    Existing member continuity: If a member was taking a drug covered at the beginning of the coverage year, Priority Health generally will not discontinue or reduce coverage for that drug for the remainder of the coverage year except in specified circumstances (e.g., market withdrawal or substitution with an approved generic/biosimilar).

    Stability of coverage during the coverage year for current users.

    Transition supply during coverage changes: Members experiencing a level-of-care change will be provided a transition supply of at least 30 days of medication unless the prescription is written for fewer days; long-term care residents may receive a 31-day emergency supply for non-formulary drugs while pursuing an exception.30 days

    Applies to transitions and care-level changes.

    Step Therapy Rules and Notes

    Step therapy summarySource / notes
    Try specified drugs first before covering alternatives (Step Therapy may require trial of preferred agent(s) prior to coverage of non-preferred products).
    Formulary describes ST in general terms and explains that members may need to try Drug A before Drug B; see 'Are there any restrictions on my coverage?' and abbreviation definitions for ST.
    Therapeutic classes / examples with STSource / notes
    Some therapeutic classes use Step Therapy; members may be required to try preferred antidepressants (examples: FETZIMA, vilazodone, TRINTELLIX) before coverage of other agents.
    Abbreviation key defines ST and class entries (FETZIMA, vilazodone, TRINTELLIX) show Requirements/Limits = ST in the formulary listings.
    ProductST details
    DIFICID oral suspension (fidaxomicin)
    Requirements/Limits = ST; QL (136 ML per 10 days).
    Product / classST indication
    FETZIMA (antidepressant)
    Requirements/Limits = ST; QL (30 EA per 30 days) indicated in formulary excerpt.
    TRINTELLIX / vilazodone (antidepressants)
    Some entries show Requirements/Limits = ST (step therapy) for selected antidepressant products in the formulary listings.
    eletriptan (triptan class) and related agents
    Formulary notes include 'ST' for certain triptans/antimigraine agents (ST applies where listed).
    Legend / definitionImplication
    ST = Step Therapy (formulary abbreviation defined in legend).
    Legend indicates ST is a possible utilization control but specific step rules are not listed in the excerpt; follow ST where shown on product rows.
    Product / strengthST note
    paliperidone ER 1.5 mg, 3 mg, 9 mg
    Requirements/Limits = ST; QL (30 EA per 30 days) — ST required for certain paliperidone ER strengths per formulary listing.
    paliperidone ER 6 mg
    Requirements/Limits = ST; QL (60 EA per 30 days) — strength-specific ST and QL noted in the entry.
    ST in legendComment
    ST is included in the formulary abbreviation list (ST = Step Therapy).
    The legend references ST as a requirement code; specific product-level rules must be read on individual drug rows.
    ReferenceDetail
    Abbreviation key (ST)
    ST (Step Therapy) appears in the abbreviation key and may apply to products elsewhere in the full formulary; no full ST protocol is provided in excerpt.
    ObservationSource
    Step Therapy (ST) may apply to drugs listed in other parts of the formulary not included in this excerpt.
    Legend and abbreviation references indicate ST is a recognized requirement code; specific drug rows elsewhere will show ST when applicable.
    ProductRequirements/Limits
    calci triol external (calcitriol external products)
    Requirements/Limits = ST (step therapy) noted in formulary excerpt for calcitriol external product.
    ExampleST application
    ST. clotrimazole-betamethasone external cream
    Formulary header/example shows ST applied where indicated (follow ST requirement on product row); QL also specified for clotrimazole-betamethasone cream (120 GM per 30 days).
    Abbreviation keyNote
    ST listed in the abbreviation key (Step Therapy).
    Formulary notes ST among other requirement codes; specific application depends on product-row flags.
    AreaST usage
    Ophthalmic agents and anti-inflammatories
    ST is applied to selected ophthalmic agents (e.g., travoprost flagged ST; loteprednol and difluprednate entries show ST); follow product row ST requirements for authorization.
    Ophthalmic examplesDetails
    travoprost (ophthalmic prostaglandin)
    Listed with Requirements/Limits = ST in ophthalmic prostaglandin section; formulary indicates ST applies to selected prostaglandin agents.
    difluprednate / loteprednol (ophthalmic anti-inflammatories)
    Entries for difluprednate and loteprednol show Requirements/Limits = ST for some formulations in the ophthalmic anti-inflammatory listings.
    StatementFormulary context
    ST referenced in legend but specific ST protocol not included in excerpt.
    Multiple product rows (e.g., paliperidone ER, ZYPREXA RELPREVV) include requirement codes and QLs; ST appears as a possible restriction but full step rules are not provided here.

    Quantity Limits by Product (Examples)

    inv-153: multiple QL examples from excerpt
    Fentanyl transdermal patch (72‑hour) — multiple strengthsQL 10 EA per 30 days
    Lidocaine external patch 5% / LIDOCANRequirements: PA; QL 90 EA per 30 days
    ARIKAYCE (amikacin liposome inhalation)Requirements: PA; QL 235.2 ML per 28 days
    inv-154: XIFAXAN 200 MG — QL examples
    XIFAXAN 200 mgQL 9 EA per 30 days; PA required
    XIFAXAN 550 mgQL 60 EA per 30 days; PA required
    Brivaracetam oral solutionQL 600 ML per 30 days; PA required
    inv-160: eslicarbazepine acetate — QL examples
    Eslicarbazepine acetate (200/400 mg)QL 30 EA per 30 days
    Eslicarbazepine acetate (600/800 mg)QL 60 EA per 30 days
    Lacosamide oral solutionQL 1200 ML per 30 days
    inv-171: INVEGA HAFYERA and RELPREVV examples
    INVEGA HAFYERA 1092 mg/3.5 MLQL 3.5 ML per 180 days
    ZYPREXA RELPREVV 210/300/405 mg (IM recon)QL 2 EA (210 mg) / 2 EA (300 mg) / 1 EA (405 mg) per 30 days
    VERSACLOZQL 540 ML per 30 days; Requirements: PA

    Site-of-Care and Benefit Routing

    Note
    Note
    Note
    Note